

HPV vaccine cost and procurement – transitioning out of Gavi support and self-procurement

Didik Setiawan, HEWG ITAGI (Indonesia)








d.didiksetiawan@gmail.com



Introduction

- HPV types 16 & 18 cause ~ 70% of cervical cancer cases worldwide.
- In Indonesia: 36,000 new cases & 18,000 deaths annually (Globocan 2020).
- Cervical cancer is the 2nd most common cancer among women.
- HPV Vaccine: 90-100% effective in preventing precancerous lesions.
- Vaccination Program: Part of national immunization for pre-adolescent girls (11-12).
- Public Health Impact: Prevents thousands of cases & reduces long-term healthcare costs.



GAVI support phase (Indonesia)

Initial support phase

Accelerated transition phase (2016 – 2026)



Full self-financing and graduation (expected in 2026)



Vaccine Procurement Health
Systems
Strengthening

Technical and Strategic Assistance

Increase cofinancing

HPV Vaccine cost-structure

Table 2. The vaccination cost component of HPV vaccine.

Cost component	GAVI/UNICEF Price*	Government contract price*
Vaccine price	4.50	11.62
Shipping cost	0.16	0.00
Handling fee	0.41	
Insurance	0.23	

^{*}Vaccine price using Gardasil® price for the budget impact analysis.

https://doi.org/10.1371/journal.pone.0230359.t002

Procurement Strategies Post-Gavi

Technology Transfer and Local Production

 Training, facility upgrades, regulatory compliance, and eventual large-scale local production for the national immunization program.

Challenges in Self-Procurement

- Ensuring consistent supply
- Concern: maintaining quality and budget



biofarma

HPV Vaccination policy in Indonesia

Years of Implementation	2019	2020	2021	2022	2023	2024
Scenario 1	DKI Jakarta	DKI Jakarta (p)	DKI Jakarta (p)	DKI Jakarta (p)	DKI Jakarta (p)	DKI Jakarta (p)
(Two districts per year) Sura Mak Man Gn K Kulo Bant Slem	(p) Surabaya Makassar Manado Gn Kidul Kulon Progo	Surabaya Makassar Manado DIY (p) Karanganyar* Sukoharjo*	Surabaya Makassar Manado DIY (p) Karanganyar Sukoharjo			
	Bantul* Sleman* Yogyakarta*		Kediri* Lamongan*	Kediri Lamongan Batam* Tj Pinang*	Kediri Lamongan Batam Tj Pinang Jambi* Muara Jambi*	Kediri Lamongan Batam Tj Pinang Jambi Muara Jambi Banjarbaru* Banjarmasin*

Health Minister announce the Nationwide vaccination program including HPV (2022)

Menkes Budi Targetkan Vaksin Kanker Serviks Sasar Seluruh Daerah pada 2023

Target vaksin HPV untuk cegah kanker serviks menyasar seluruh daerah pada 2023.











Share 11



HPV Vaccination policy in Indonesia

Years of Implementation	2019	2020	2021	2022	2023	2024
	DKI Jakarta (p) Surabaya Makassar Manado Gn Kidul Kulon Progo Bantul* Sleman* Yogyakarta*	DKI Jakarta (p) Surabaya Makassar Manado DIY (p) Karanganyar* Sukoharjo*	DKI Jakarta (p) Surabaya Makassar Manado DIY (p) Karanganyar Sukoharjo Kediri* Lamongan*	DKI Jakarta (p) Surabaya Makassar Manado DIY (p) Karanganyar Sukoharjo Kediri Lamongan Batam* Tj Pinang*	Nationwide	Nationwide plus MAC


cMYP 2020 - 2024

The cMYP 2020 - 2024

Projection cost for new vaccines is 70.5% of total vaccine cost in 2024

- 42.6% for HPV
- 14.8% for PCV
- 13.1% for Rotavirus


Expenditure for total vaccines cost 2017-2021



budget);

20,1%

.....



New

vaccine (Gavi);

The Central Government responsible for the provision of vaccines (MoH Decree No. 12/2017)

Routine

Vaccine

(state

budget);

64,1%

HPV Vaccination Roadmap

Tahun	2023	2024	2025	2026	2027	2028	2029	2030
Coverage					90%			
Umur (thn)	1	2	3	4	5	6	7	8
	2	3	4	5	6	7	8	9
	3	4	5	6	7	8	9	10
	4	5	6	7	8	9	10	11
	5	6	7	8	9	10	11	12
	6	7	8	9	10	11	12	13
	7	8	9	10	11	12	13	14
	8	9	10	11	12	13	14	15
	9	10	11	12	13	14	15	16
	10	11	12	13	14	15	16	17
	11	12	13	14	15	16	17	18
	12	13	14	15	16	17	18	19
	13	14	15	16	17	18	19	20
	14	15	16	17	18	19	20	21
	15	16	17	18	19	20	21	22
	16	17	18	19	20	21	22	23
	17	18	19	20	21	22	23	24

-	
	2nd dose for target population in the pilot area
	Primary target group
	Secondary target group
	Missed the opportunity (catching up)



Discussion

- HPV vaccine price
- ITAGI plays important role on Vaccination policy In Indonesia.
 - Open recommendation for all types of HPV vaccines
 - Single dose has been recommended
- Strong political will is substantial in Indonesia.
 - Nationwide implementation
 - Additional budget for HPV vaccine
- Some uncertainty
 - Secure budget??